Karyopharm Therapeutics Inc (FRA:25K)
€ 0.8862 0.0364 (4.28%) Market Cap: 115.58 Mil Enterprise Value: 141.61 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

Karyopharm Therapeutics Inc - Discuss Selinexor As A Potential Treatment For Hospitalized Patients With COVID-19 Transcript

Apr 07, 2020 / 12:30PM GMT
Release Date Price: €17.8 (+4.71%)
Operator

Good morning. My name is Cherie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics COVID-19 Clinical Trial Initiation Conference Call. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Mr. Ian Karp, Karyopharm's Vice President, Investor and Public Relations.

Ian Karp
Karyopharm Therapeutics Inc. - VP of Investor & Public Relations

Thank you, Cherie, and thank you all for joining us on today's conference call to discuss the initiation of a new clinical trial to evaluate low-dose selinexor as a potential treatment for hospitalized patients with COVID-19. This is Ian Karp, and I'm joined today by Dr. Michael Kauffman, our Chief Executive Officer; Dr. Sharon Shacham, President and Chief Scientific Officer; and Dr. Jatin Shah, Chief Medical Officer.

On the call today, Dr. Kauffman will provide a brief overview of the scientific rationale for our new clinical

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot